Biotech | January 10, 2022
Novartis and Molecular Partners report positive data for anti-viral Covid therapy
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
